The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Challenges in implementing universal lung cancer biomarker testing
Matthew Smeltzer, PhD, University of Memphis, Memphis, TN, comments on barriers to widespread biomarker testing for lung cancer. Clinicians may have reservations in terms of the cost to benefit ratio and more education is recommended for them, especially if they have not been updated on novel techniques such as next-generation sequencing (NGS). Dr Smeltzer additionally highlights the need to implement policies that make biomarker testing more affordable for healthcare providers and other related stakeholders. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
